These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25012071)

  • 1. Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas.
    Hill VK; Shinawi T; Ricketts CJ; Krex D; Schackert G; Bauer J; Wei W; Cruickshank G; Maher ER; Latif F
    BMC Cancer; 2014 Jul; 14():506. PubMed ID: 25012071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
    Noushmehr H; Weisenberger DJ; Diefes K; Phillips HS; Pujara K; Berman BP; Pan F; Pelloski CE; Sulman EP; Bhat KP; Verhaak RG; Hoadley KA; Hayes DN; Perou CM; Schmidt HK; Ding L; Wilson RK; Van Den Berg D; Shen H; Bengtsson H; Neuvial P; Cope LM; Buckley J; Herman JG; Baylin SB; Laird PW; Aldape K;
    Cancer Cell; 2010 May; 17(5):510-22. PubMed ID: 20399149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
    Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A
    J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.
    Li R; Li H; Yan W; Yang P; Bao Z; Zhang C; Jiang T; You Y
    Oncotarget; 2015 Mar; 6(9):7318-24. PubMed ID: 25821160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
    Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
    Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
    Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
    Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation profiles of long- and short-term glioblastoma survivors.
    Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F
    Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
    Laffaire J; Everhard S; Idbaih A; Crinière E; Marie Y; de Reyniès A; Schiappa R; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Thillet J; Ducray F
    Neuro Oncol; 2011 Jan; 13(1):84-98. PubMed ID: 20926426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
    Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
    Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.
    Ohno M; Narita Y; Miyakita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Shibui S
    Brain Tumor Pathol; 2013 Oct; 30(4):224-32. PubMed ID: 23494632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
    Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
    Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
    World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
    Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
    PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis.
    Hill VK; Underhill-Day N; Krex D; Robel K; Sangan CB; Summersgill HR; Morris M; Gentle D; Chalmers AD; Maher ER; Latif F
    Oncogene; 2011 Feb; 30(8):978-89. PubMed ID: 20956940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
    Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
    Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression.
    Alentorn A; Durán-Peña A; Malousi A; Marie Y; Mokhtari K; Sanson M; Hoang-Xuan K; Delattre JY; Idbaih A; Vecht C
    J Neurooncol; 2015 Sep; 124(3):385-92. PubMed ID: 26224161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.